Radioimmunotherapy: A novel treatment of non-Hodgkin lymphoma
Bibliographic record
Abstract
90Y-ibritumomab tiuxetan (Zevalin) and 131I-tositumomab (Bexxar) are current choices for radioimmunotherapy (RIT) of patients with follicular rituximab-relapsed or refractory CD20+ follicular B-cell NHL. Bexxar is available in the United States and Canada, while Zevalin was approved for use only in Europe. The Zevalin regimen consists of rituximab ('cold', chimeric antibody) and 90Y-ibritumomab tiuxetan ('hot' antibody). In Bexxar regimen, a tositumomab (murine antibody) is used as both, the unlabelled and labelled antibody. In both cases, the therapeutic infusion of 'hot' or radiolabelled component is preceded one week earlier by an infusion of a 'cold' or unlabelled antibody. In the US, the whole-body scanning using 111In-ibritumomab following the initial rituximab infusion is required for determination of biodistribution before the therapeutic dose of Zevalin. Bexxar regimen includes three whole body scans during the week after an imaging dose of 131I-tositumomab, which are necessary for calculation of the therapeutic dose of 131I-tositumomab. For each regimen, patients with a platelet count ?150x109/L receive a full therapeutic dose, whereas patients with platelet counts >100x109/L<150x109/L receive a modified dose of radiolabelled antibody. Therapeutic dose of Zevalin is 11-15 MBq/kg (up to maximum of 1200 MBq), while the dose of Bexxar is 1.85-5.55 GBq (maximal tolerated absorbed dose for the whole body is 75cGy). If compared to alternative treatments, the radioimmunotherapy with Bexxar and Zevalin achieves longer time to progression and longer duration of response with overall response rate between 80% to almost 100%. Repeated treatment with Zevalin or Bexxar is possible. The additional subsequent conventional therapy is compatible. Radioimmunotherapy is radiation safe and well tolerated treatment with primarily transient haematological adverse events. Pregnancy and lactation are contraindications for radioimmunotherapy. Beta radiation of 90Y allows treatment on outpatient basis.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".